We are live on ! Find out more
PACB icon

Pacific Biosciences
PACB

109 hedge funds and large institutions have $206M invested in Pacific Biosciences in 2017 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 33 increasing their positions, 31 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

92% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 13

11% more funds holding

Funds holding: 98 → 109 (+11)

6% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 31

3.92% less ownership

Funds ownership: 70.91% → 66.99% (-3.9%)

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

52% less capital invested

Capital invested by funds: $430M → $206M (-$225M)

96% less call options, than puts

Call options by funds: $42K | Put options by funds: $1.06M

Holders
109
Holders Change
+11
Holders Change %
+11.22%
% of All Funds
2.47%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.05%
New
25
Increased
33
Reduced
31
Closed
13
Calls
$42K
Puts
$1.06M
Net Calls
-$1.02M
Net Calls Change
+$674K

Top Buyers

1
ACH
ArrowMark Colorado Holdings
Colorado
+$2.79M
2
MC
Maverick Capital
Texas
+$2.17M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$1.23M
4
SIM
Spark Investment Management
New York
+$935K
5
IG
ING Group
Netherlands
+$728K

Top Sellers

1
RCM
Raging Capital Management
New Jersey
-$4.32M
2
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
-$4.28M
3
BlackRock
BlackRock
New York
-$4.27M
4
Invesco
Invesco
Georgia
-$3.52M
5
SFM
Soros Fund Management
New York
-$3.52M
Name Holding Trade Value Shares
Change 		Change in
Stake
MC
1
Maverick Capital
Texas
$29.6M +$2.17M +619,150 +6%
OIM
2
Oracle Investment Management
Connecticut
$22.3M -$816K -233,080 -3%
BlackRock
3
BlackRock
New York
$21.5M -$4.27M -1,219,392 -13%
Capital World Investors
4
Capital World Investors
California
$21.5M – – –
CCM
5
Consonance Capital Management
New York
$18.7M +$576K +164,492 +2%
Vanguard Group
6
Vanguard Group
Pennsylvania
$12.9M +$1.23M +351,297 +8%
Invesco
7
Invesco
Georgia
$11M -$3.52M -1,006,412 -19%
ACH
8
ArrowMark Colorado Holdings
Colorado
$10.3M +$2.79M +795,699 +26%
RCM
9
Raging Capital Management
New Jersey
$8.42M -$4.32M -1,232,968 -28%
Blackstone Inc
10
Blackstone Inc
New York
$6.37M – – –
State Street
11
State Street
Massachusetts
$4.77M +$594K +169,788 +10%
FCM
12
Frontier Capital Management
Massachusetts
$3.85M -$99K -28,287 -2%
Northern Trust
13
Northern Trust
Illinois
$3.18M -$200K -57,029 -5%
TA
14
Teachers Advisors
New York
$2.72M +$76.5K +21,835 +2%
Geode Capital Management
15
Geode Capital Management
Massachusetts
$2.46M +$201K +57,374 +7%
TMC
16
Trellus Management Company
Florida
$1.72M +$438K +125,000 +24%
MOACM
17
Mutual of America Capital Management
New York
$1.35M +$99.4K +28,384 +6%
California Public Employees Retirement System
18
California Public Employees Retirement System
California
$1.21M – – –
FCMI
19
Foresite Capital Management III
California
$1.18M -$2.46M -702,480 -61%
Deutsche Bank
20
Deutsche Bank
Germany
$1.13M +$699K +199,717 +87%
Charles Schwab
21
Charles Schwab
California
$1.13M +$65K +18,564 +5%
Bank of New York Mellon
22
Bank of New York Mellon
New York
$1.1M -$144K -41,152 -9%
CLOS
23
Compagnie Lombard Odier SCmA
Switzerland
$790K +$525K +150,000 +100%
Fuller & Thaler Asset Management
24
Fuller & Thaler Asset Management
California
$770K -$328K -93,655 -24%
BLAM
25
Bourne Lent Asset Management
New York
$769K +$312K +89,002 +44%
1
2 3 4 5

PACB Hedge Fund Activity: Q4 2017 in Review

109 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q4 2017, worth a combined $206M — down 52% from $430M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new PACB positions and 13 closed out — a net gain of 12 holders — while 33 added to existing stakes and 31 trimmed.

The largest buyer was ArrowMark Colorado Holdings, adding an estimated $2.79M. The largest seller was Raging Capital Management, cutting an estimated $4.32M.

  • 109 institutional investors held Pacific Biosciences (PACB) as of Q4 2017, up from 98 in Q3 2017.
  • Funds reported $206M of Pacific Biosciences stock for Q4 2017, down 52% quarter-over-quarter.
  • 25 funds opened new Pacific Biosciences positions in Q4 2017 and 13 closed out, a net change of +12 holders.
  • The largest Pacific Biosciences buyer in Q4 2017 was ArrowMark Colorado Holdings, an estimated $2.79M added.
  • The largest Pacific Biosciences seller in Q4 2017 was Raging Capital Management, an estimated $4.32M sold.

Based on aggregated 13F filings for Q4 2017.